The Australian Competition and Consumer Commission has appealed a judge’s decision throwing out its competition case over an agreement for the privatisation of two NSW ports, calling the case “a matter of significance for the Australian economy”.
Queensland crane company NQCranes wants to strike out the bulk of the ACCC’s amended case alleging a conspiracy with a multinational rival to divide the Brisbane and Newcastle markets, saying there was no evidence of the regulator’s new allegations of a second cartel agreement.
The ACCC has brought Federal Court action against major milk processor Lactalis Australia, the regulator’s first case for breaches of the dairy code of conduct.
The number of lawyers involved in a class action against 3A Composites over allegedly combustible cladding is set to balloon, with the German cladding manufacturer lobbing cross-claims against nine different parties.
A judge has hit women’s activewear company Lorna Jane with a $5 million penalty for representing to consumers during the height of the coronavirus crisis last year that its activewear would protect them from viruses including COVID-19.
Google is pressing forward with an application to stay Fortnite game maker Epic Games’ competition lawsuit over its Google Play store terms, despite the Full Court rejecting a similar move by Apple.
The ACCC will probe potential competition and consumer concerns over online retail platforms eBay, Amazon, Kogan and Catch.com.au, and has called for submissions as part of its ongoing inquiry into digital platform services.
Sydney lawyer Leigh Johnson has lost her appeal in a class action launched by investors who allegedly sank $12.3 million into a fraudulent sports betting scheme run by convicted conman Peter Foster.
The ACCC’s claim that NSW Ports stymied competition when it signed a 50-year agreement with the state to be compensated if the Port of Newcastle built a container terminal was based on “mere speculative hopes”, a judge found in tossing the competition watchdog’s regulatory action.
Merck Sharp & Dohme has filed a lawsuit accusing rival drug company Bristol-Myers Squibb of misusing its market power by restricting access to a treatment program for stage IV melanoma patients.